InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by Meckler Jeffrey A, Chief Executive Officer. Officer active across 2 companies, notably Travere Therapeutics, Inc.. Cumulatively, 8 disclosures have been logged. Total volume traded: €306k. The latest transaction was disclosed on 6 June 2022 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations8 total
€48,52719,727 shares@ €2.45990.95% mcap15.9% of flow
Common stock
SEC:0001493152-22-016027:0·
Ideal exit: 3 Mar 2023 (T+270)
03,000 shares0
Common Stock
SEC:0001209191-22-028697:0·
€57,51011,187 shares@ €5.140844.7% of flow
Common Stock
SEC:0001493152-21-029297·
Ideal exit: 15 Aug 2022 (T+270)
€57,51011,187 shares@ €5.14081.13% mcap18.8% of flow
Common Stock
SEC:0001493152-21-029297:0·
Ideal exit: 15 Aug 2022 (T+270)
€71,15612,000 shares@ €5.929755.3% of flow
Common Stock
SEC:0001493152-21-022936·
Ideal exit: 11 Jun 2022 (T+270)
€71,15612,000 shares@ €5.92971.40% mcap23.3% of flow
Common Stock
SEC:0001493152-21-022936:0·
Ideal exit: 11 Jun 2022 (T+270)
03,000 shares0
Common Stock
SEC:0001209191-21-033849·
03,000 shares0
Common Stock
SEC:0001209191-21-033849:0·
8 of 8 declarations
About Meckler Jeffrey A
Jeffrey A. Meckler is President and CEO of Travere Therapeutics, Inc. and Indaptus Therapeutics, Inc. In these roles, he is responsible for the strategic and operational leadership of both companies. Jeffrey plays a key role in defining growth objectives and optimizing performance. His leadership is essential for ensuring the long-term success of Travere and Indaptus.
